Company: BLRX
Filing Date: 2025-03-31
Form Type: 20-F
Source: 0001178913-25-001123
Chunk: 346

Company: BioLineRx Ltd.
Filing Date: 2025-03-31
Form: 20-F
Item: Item 19
Chunk 346
---
’s specific market share, either via direct sales or a potential out-licensing deal.
In light of the Company’s decision to terminate AGI-134, the value of its intangible asset was written off in its entirety in 2023.
As a result of an impairment review of its remaining rights to motixafortide in solid tumor indications in the fourth quarter of 2024, the Company recorded an impairment loss (see Note 9).
Fair value estimations of warrants
As described in Notes 3d and 12c, the Company completed financing transactions in which it issued ADSs and warrants to purchase additional ADSs. The fair value of the warrants, which are not traded on an active market, is determined by using valuation techniques. These valuation techniques maximize the use of observable market data where it is available and rely as little as possible on entity specific estimates.
License revenue recognition
In determining the amounts to be recognized as revenue relating to the out-licensing transactions with HST and Gloria, the Company was required to use significant judgement in the following matters:
The allocation of consideration between the license agreement and the SPA, based on the fair value of the Company’s shares on the date considered as the closing date of the transaction
The estimated stand-alone, selling-price value between the contract components (i. e., between the main therapeutic areas covered by the contract), as well as the performance obligations relatin...
The period of time over which revenue should be recognized for each component. The revenue recognition method is the ratio of support hours to the total hours expected to be incurred.
Similar judgement (with the exception of the second and third bullets above, which were not relevant) was required in determining the amounts to be recognized as revenue relating to the out-licensing transaction with Ayrmid.
Recognition and measurement of allowance for rebates, chargebacks and returns
The Company makes several key estimations related to gross-to-net (GTN) revenue, which are recognized as revenue reductions and for which unsettled amounts are accrued. The primary measures calculated include rebates, Medicaid and other governmental rebates, chargebacks, and returns.
The allowance is calculated based on common practices in the industry and the estimated utilization of rebate and chargeback programs at the time revenue is recognized. The main estimates used in recognizing and measuring this allowance relate to the volume of products sold to distributors but not yet prescribed to patients. The Company periodically evaluates its estimates against actual results and updates them accordingly as necessary.

NOTE 5 - CASH AND CASH EQUIVA